132 related articles for article (PubMed ID: 37732614)
1. Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.
Tomasulo E; Paul S; Mu R; Tian X; Chen J; Pleyer C; Wiestner A; Sun C
Leuk Lymphoma; 2023 Dec; 64(14):2306-2315. PubMed ID: 37732614
[TBL] [Abstract][Full Text] [Related]
2. Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.
Campanella A; Capasso A; Heltai S; Taccetti C; Albi E; Herishanu Y; Haggenburg S; Chatzikonstantinou T; Doubek M; Kättström M; Giannopoulos K; Simkovic M; Moreno C; Massaia M; Bumbea H; Alshemmari S; Ranghetti P; Perotta E; Martini F; Sant'Antonio E; Colia M; Combi C; Levi S; Kater AP; Hazenberg M; Nijhof IS; Hofsink Q; Demosthenous C; Kotaskova J; Zaleska J; Vrbacky F; Raya AM; Bisogno D; Tripoli IE; Popov VM; Roman V; Stavroyianni N; Karypidou M; Scarano E; Locatelli M; Frenquelli M; Scarfò L; Stamatopoulos K; Ghia P
Am J Hematol; 2024 Apr; 99(4):745-750. PubMed ID: 38264829
[TBL] [Abstract][Full Text] [Related]
3. Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination.
Lee HK; Hoechstetter MA; Buchner M; Pham TT; Huh JW; Müller K; Zange S; von Buttlar H; Girl P; Wölfel R; Brandmeier L; Pfeuffer L; Furth PA; Wendtner CM; Hennighausen L
Blood Adv; 2023 May; 7(10):2214-2227. PubMed ID: 36630562
[TBL] [Abstract][Full Text] [Related]
4. Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study.
Doukas PG; St Pierre F; Karmali R; Mi X; Boyer J; Nieves M; Ison MG; Winter JN; Gordon LI; Ma S
Oncologist; 2023 Oct; 28(10):e930-e941. PubMed ID: 37141401
[TBL] [Abstract][Full Text] [Related]
5. Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia.
Barber VS; Peckham N; Duley L; Francis A; Abhishek A; Moss P; Cook JA; Parry HM
BMJ Open; 2023 Sep; 13(9):e077946. PubMed ID: 37770269
[TBL] [Abstract][Full Text] [Related]
6. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
[TBL] [Abstract][Full Text] [Related]
7. Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.
Bennett R; Anderson MA; Seymour JF
J Hematol Oncol; 2023 Jul; 16(1):72. PubMed ID: 37422670
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
Mato AR; Roeker LE; Jacobs R; Hill BT; Lamanna N; Brander D; Shadman M; Ujjani CS; Yazdy MS; Perini GF; Pinilla-Ibarz JA; Barrientos J; Skarbnik AP; Torka P; Pu JJ; Pagel JM; Gohil S; Fakhri B; Choi M; Coombs CC; Rhodes J; Barr PM; Portell CA; Parry H; Garcia CA; Whitaker KJ; Winter AM; Sitlinger A; Khajavian S; Grajales-Cruz AF; Isaac KM; Shah P; Akhtar OS; Pocock R; Lam K; Voorhees TJ; Schuster SJ; Rodgers TD; Fox CP; Martinez-Calle N; Munir T; Bhavsar EB; Bailey N; Lee JC; Weissbrot HB; Nabhan C; Goodfriend JM; King AC; Zelenetz AD; Dorsey C; Bigelow K; Cheson BD; Allan JN; Eyre TA
Clin Cancer Res; 2020 Jul; 26(14):3589-3596. PubMed ID: 32198151
[TBL] [Abstract][Full Text] [Related]
9. Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia.
Molica S; Tam C; Polliack A
Hematol Oncol; 2022 Aug; 40(3):313-319. PubMed ID: 35304771
[TBL] [Abstract][Full Text] [Related]
10. BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).
Chong EA; Roeker LE; Shadman M; Davids MS; Schuster SJ; Mato AR
Clin Cancer Res; 2020 Jul; 26(14):3514-3516. PubMed ID: 32345646
[TBL] [Abstract][Full Text] [Related]
11. Effects of the BTN162b2 mRNA COVID-19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia.
Fiorcari S; Atene CG; Maffei R; Mesini N; Debbia G; Colasante C; Pozzi S; Barbieri E; Maccaferri M; Leonardi G; Potenza L; Luppi M; Marasca R
Hematol Oncol; 2023 Feb; 41(1):120-127. PubMed ID: 36156278
[TBL] [Abstract][Full Text] [Related]
12. BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL.
Pleyer C; Laing KJ; Ali MA; McClurkan CL; Soto S; Ahn IE; Nierman P; Maddux E; Lotter J; Superata J; Tian X; Wiestner A; Cohen JI; Koelle DM; Sun C
Blood Adv; 2022 Mar; 6(6):1732-1740. PubMed ID: 35157769
[TBL] [Abstract][Full Text] [Related]
13. Frontline treatment in CLL: the case for time-limited treatment.
Lévy V; Delmer A; Cymbalista F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):59-67. PubMed ID: 34889444
[TBL] [Abstract][Full Text] [Related]
14. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
Herishanu Y; Avivi I; Aharon A; Shefer G; Levi S; Bronstein Y; Morales M; Ziv T; Shorer Arbel Y; Scarfò L; Joffe E; Perry C; Ghia P
Blood; 2021 Jun; 137(23):3165-3173. PubMed ID: 33861303
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.
Herishanu Y; Rahav G; Levi S; Braester A; Itchaki G; Bairey O; Dally N; Shvidel L; Ziv-Baran T; Polliack A; Tadmor T; Benjamini O;
Blood; 2022 Feb; 139(5):678-685. PubMed ID: 34861036
[TBL] [Abstract][Full Text] [Related]
17. T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents.
Schiavoni I; Palmieri A; Olivetta E; Leone P; Di Lonardo A; Mazzoli A; Cafariello C; Malara A; Palamara AT; Incalzi RA; Onder G; Stefanelli P; Fedele G;
J Am Med Dir Assoc; 2023 Feb; 24(2):140-147.e2. PubMed ID: 36587928
[TBL] [Abstract][Full Text] [Related]
18. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies.
Terpos E; Fotiou D; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Gavriatopoulou M; Malandrakis P; Iconomidou VA; Kastritis E; Trougakos IP; Dimopoulos MA
Am J Hematol; 2022 Oct; 97(10):1300-1308. PubMed ID: 35871310
[TBL] [Abstract][Full Text] [Related]
20. Approaches for relapsed CLL after chemotherapy-free frontline regimens.
Roeker LE; Mato AR
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):10-17. PubMed ID: 33275712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
